爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EW 爱德华兹

盘后交易 11-13 16:55:54 EST

107.15

+1.35

+1.28%

盘后106.59

-0.56-0.52%

16:51 EST

最高107.69	最低106.01	成交量382.13万
今开106.11	昨收105.80	日振幅1.59%
总市值617.76亿	流通市值616.14亿	总股本5.77亿
成交额4.09亿	换手率0.66%	流通股本5.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EW","market":"US","secType":"STK","nameCN":"爱德华兹","latestPrice":107.15,"timestamp":1794603600000,"preClose":105.8,"halted":0,"volume":3821330,"hourTrading":{"tag":"盘后","latestPrice":106.59,"preClose":107.15,"latestTime":"16:51 EST","volume":70025,"amount":7502925.959749999,"timestamp":1794606683498,"change":-0.56,"changeRate":-0.005226,"amplitude":0.014092},"delay":0,"changeRate":0.01275992438563335,"floatShares":575029897,"shares":576541693,"eps":1.761636,"marketStatus":"盘后交易","change":1.35,"latestTime":"11-13 16:55:54 EST","open":106.105,"high":107.69,"low":106.01,"amount":409294379.29921997,"amplitude":0.015879,"askPrice":108.1,"askSize":2,"bidPrice":106.7,"bidSize":2,"shortable":3,"etf":0,"ttmEps":1.761636,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1794618000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":105.8,"preHourTrading":{"tag":"盘前","latestPrice":106.67,"preClose":105.8,"latestTime":"09:24 EST","volume":493,"amount":52397.205452,"timestamp":1794579858219,"change":0.87,"changeRate":0.008223,"amplitude":0.008223},"postHourTrading":{"tag":"盘后","latestPrice":106.59,"preClose":107.15,"latestTime":"16:51 EST","volume":70025,"amount":7502925.959749999,"timestamp":1794606683498,"change":-0.56,"changeRate":-0.005226,"amplitude":0.014092},"volumeRatio":0.795974,"impliedVol":0.2951,"impliedVolPercentile":0.3466},"requestUrl":"/m/hq/s/EW","defaultTab":"news","newsList":[{"id":"1194053838","title":"异动解读｜爱德华兹盘中上涨3.02%，券商上调目标价强化乐观预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1194053838","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194053838?lang=zh_cn&edition=full","pubTime":"2026-11-10 03:59","pubTimestamp":1794254341,"startTime":"0","endTime":"0","summary":"11月10日，爱德华兹盘中上涨3.02%，报105.26美元/股，成交额3.67亿美元。最新消息面上，Piper Sandler将爱德华兹目标价上调至115美元，高于此前101美元；此前公司第三季度调整后每股收益0.80美元、营收17.16亿美元，均高于市场预期，进一步支撑市场情绪。同时，公司全年调整后每股收益指引收窄至2.97美元至3.05美元，市场一致预期约为3美元。叠加此前Truist将评级上调至买入并把目标价升至113美元，说明机构对其结构性心脏病产品线及增长前景的看法趋于积极。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"爱德华兹财报超预期，券商上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162987083","title":"异动解读｜爱德华兹盘中上涨3.27%，Piper Sandler上调目标价至115美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162987083","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162987083?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:43","pubTimestamp":1793889809,"startTime":"0","endTime":"0","summary":"11月5日，爱德华兹盘中上涨3.27%，报102.75美元/股，成交额4744.65万美元。消息面上，Piper Sandler将公司目标价由101美元上调至115美元，高于FactSet统计的111.04美元平均目标价，直接提振市场情绪。此前公司披露三季度调整后每股收益0.80美元、营收17.2亿美元，均高于市场预期的0.74美元和16.8亿美元，强化了机构上调目标价的基础；不过公司第四季度指引区间对应的每股收益中枢略低于市场预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"爱德华兹获上调目标价，盘中拉升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162564480","title":"异动解读｜爱德华兹盘前上涨3.9%，三季度业绩超预期带动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1162564480","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162564480?lang=zh_cn&edition=full","pubTime":"2026-11-05 17:56","pubTimestamp":1793872605,"startTime":"0","endTime":"0","summary":"11月5日，爱德华兹盘前上涨3.9%，报103.2935美元/股，成交额3.25万美元。消息面上，公司最新披露的三季度业绩整体好于市场预期。整体看，市场更关注本季业绩超预期带来的短线提振。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"爱德华兹业绩超预期，盘前股价走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135075547","title":"异动解读｜爱德华兹盘后下跌3.39%，Truist上调评级至买入后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1135075547","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135075547?lang=zh_cn&edition=full","pubTime":"2026-11-05 05:19","pubTimestamp":1793827142,"startTime":"0","endTime":"0","summary":"11月5日，爱德华兹盘后下跌3.39%，报97.17美元/股，成交额2605.36万美元。消息面上，Truist Securities此前将公司评级从持有上调至买入，并将目标价由95美元上调至113美元，带动该股当日交易时段一度上涨4.6%，股价触及99.58美元，成交量约430万股，高于日均约350万股。近期公司催化还包括PASCAL Precision三尖瓣修复系统获FDA批准，以及Progress试验显示TAVR在中度主动脉瓣狭窄患者中较临床监测实现主要复合终点33%的相对降幅，强化了其中长期产品增长预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹盘后下跌，评级上调难阻回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139389208","title":"异动解读｜爱德华兹盘中上涨3.59%，Truist上调评级至买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1139389208","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139389208?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:46","pubTimestamp":1793803603,"startTime":"0","endTime":"0","summary":"11月4日，爱德华兹盘中上涨3.59%，报98.75美元/股，成交额4045.08万美元。消息面上，Truist Securities将公司评级从持有上调至买入，目标价由95美元上调至113美元，明显高于市场平均目标价102.42美元，直接提振股价表现。此次上调叠加公司近期催化持续释放，包括FDA批准PASCAL Precision三尖瓣修复系统，以及Progress试验显示TAVR在中度主动脉瓣狭窄患者中较临床监测实现主要复合终点33%的相对降幅，强化了市场对其结构性心脏病产品线和中长期增长的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹盘中上涨，获Truist上调至买入","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112831133","title":"异动解读｜爱德华兹盘前上涨3.47%，Truist上调评级至买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1112831133","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112831133?lang=zh_cn&edition=full","pubTime":"2026-11-04 21:16","pubTimestamp":1793798198,"startTime":"0","endTime":"0","summary":"11月4日，爱德华兹盘前上涨3.47%，报98.02美元/股，成交额24.34万美元。消息面上，Truist Securities将公司评级从持有上调至买入，并将目标价从95美元上调至113美元，高于FactSet统计的分析师平均目标价102.42美元。此次上调发生在公司近期催化持续释放之后，包括FDA批准PASCAL Precision三尖瓣修复系统，以及Progress试验显示TAVR在中度主动脉瓣狭窄患者中较临床监测实现主要复合终点33%的相对降幅，进一步强化市场对其结构性心脏病产品线与中长期增长的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹获上调至买入，盘前应声上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110187525","title":"异动解读｜爱德华兹盘中上涨3.01%，FDA批准三尖瓣修复系统","url":"https://stock-news.laohu8.com/highlight/detail?id=1110187525","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110187525?lang=zh_cn&edition=full","pubTime":"2026-11-03 23:56","pubTimestamp":1793721410,"startTime":"0","endTime":"0","summary":"11月3日，爱德华兹盘中上涨3.01%，报96.07美元/股，成交额1.69亿美元。消息面上，公司近期获得美国FDA批准PASCAL Precision三尖瓣修复系统，用于改善有症状重度三尖瓣反流患者的生活质量和功能状态；同时，PASCAL Ace with Capture Clarity系统也获批用于退行性二尖瓣经导管缘对缘修复。此前，其AUTUS儿童肺动脉瓣亦已获得FDA批准。持续扩充结构性心脏病产品矩阵，有助于强化其在经导管瓣膜领域布局，并为后续收入增长提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹大涨，FDA批准三尖瓣修复系统","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165136888","title":"异动解读｜爱德华兹盘中上涨3.04%，FDA批准三尖瓣修复系统","url":"https://stock-news.laohu8.com/highlight/detail?id=1165136888","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165136888?lang=zh_cn&edition=full","pubTime":"2026-11-03 00:25","pubTimestamp":1793636711,"startTime":"0","endTime":"0","summary":"11月3日，爱德华兹盘中上涨3.04%，报94.795美元/股，成交额1.49亿美元。近期消息面上，公司获得美国FDA批准PASCAL Precision三尖瓣修复系统，用于改善有症状重度三尖瓣反流患者的生活质量和功能状态；同时，PASCAL Ace with Capture Clarity系统也获批用于退行性二尖瓣经导管缘对缘修复。该进展延续了公司近期产品获批节奏，此前其AUTUS儿童肺动脉瓣也已获FDA批准。对爱德华兹而言，持续扩充结构性心脏病产品矩阵，有助于强化经导管瓣膜领域布局，并为后续收入增长提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹获FDA批准新系统，股价上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194943372","title":"异动解读｜爱德华兹盘中上涨3.01%，FDA批准三尖瓣修复系统","url":"https://stock-news.laohu8.com/highlight/detail?id=1194943372","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194943372?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:47","pubTimestamp":1793285239,"startTime":"0","endTime":"0","summary":"10月29日，爱德华兹盘中上涨3.01%，报94.54美元/股，成交额8633.89万美元。消息面上，公司此前披露，其PASCAL Precision三尖瓣修复系统获美国FDA批准，用于改善症状性重度三尖瓣反流患者的生活质量和功能状态；同时，PASCAL Ace with Capture Clarity系统也获批用于退行性二尖瓣经导管缘对缘修复。10月初，公司AUTUS儿童肺动脉瓣亦获FDA批准，市场对其结构性心脏病产品线扩容的关注度升温。公司在结构性心脏病以及重症监护和外科监护方面处于全球领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"爱德华兹异动上涨，三尖瓣修复系统获批","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673025378","title":"估值跌至十年低点！巴克莱首次覆盖26家美股医疗科技股，首选史赛克等","url":"https://stock-news.laohu8.com/highlight/detail?id=2673025378","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673025378?lang=zh_cn&edition=full","pubTime":"2026-10-08 14:15","pubTimestamp":1791440122,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，巴克莱分析师Christopher Pasquale周二首次覆盖26家美股医疗科技公司，并将史赛克和雅培列入大盘医疗科技股推荐名单。Pasquale预计，明年大型医疗科技公司营收的潜在企稳可能成为提振市场情绪、提升估值倍数的催化剂。史赛克、爱德华生命科学领衔增持名单巴克莱将史赛克和爱德华生命科学列为大盘股首选，目标价分别为375美元和110美元。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504520.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU1791710400.SGD","LU0882574055.USD","LU0058720904.USD","LU0690374615.EUR","IHI","LU2404859741.USD","LU1791710582.SGD","BK4082","LU2506952170.USD","LU2404859667.USD","EKG","LU2506951875.HKD","LU0528227936.USD","BK4566","LU0823417653.USD","LU2089984988.USD","HEAL","ABT","LU0823417737.USD","LU0950375773.USD","BK4504","LU1983299246.USD","LU2506951958.HKD","GB00B4LPDJ14.GBP","LU2506952097.USD","LU0114720955.EUR","LU2468319806.SGD","LU2362541273.HKD","EW","LU0690374961.EUR","LU2362540622.SGD","LU0432979614.USD","SYK","BK4585","LU2362541513.USD","LU0289739699.SGD","GB00B4QBRK32.GBP","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113850673","title":"异动解读｜爱德华兹盘中上涨3.08%，Medicare TAVR覆盖决定落地叠加指引重申提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1113850673","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113850673?lang=zh_cn&edition=full","pubTime":"2026-09-16 23:15","pubTimestamp":1789571738,"startTime":"0","endTime":"0","summary":"9月16日，爱德华兹生命科学盘中上涨3.08%，报88.395美元/股，成交额7674.05万美元。此前RBC Capital Markets指出，TAVR覆盖范围扩大有望推动全国手术量增长约5%，结合ACC/AHA指南更新，为增长加速提供有利条件。此外，近期多家机构上调目标价，UBS将评级升至买入、目标价110美元，Argus上调目标价至115美元，市场情绪整体偏多。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"爱德华兹上涨，TAVR覆盖落地提振信心","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130195950","title":"异动解读｜爱德华兹盘中下跌3.49%，报86.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130195950","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130195950?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:23","pubTimestamp":1788884605,"startTime":"0","endTime":"0","summary":"9月9日，爱德华兹盘中下跌3.49%，报86.76美元/股，成交额7041.55万美元。爱德华兹所在的医疗保健设备行业中，板块整体承压明显，个股中，史赛克跌7.29%，波士顿科学跌4.47%，直觉外科公司跌4.45%，雅培跌2.16%，美敦力跌1.38%。爱德华兹生命科学公司在结构性心脏病以及重症监护和外科监护方面处于全球领先地位，与世界领先的临床医生和研究人员合作，投资研发以改变对结构性心脏病患者的护理。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138688907","title":"异动解读｜爱德华兹生命科学盘中上涨3.1%，多家投行密集上调评级及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1138688907","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138688907?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:05","pubTimestamp":1785780304,"startTime":"0","endTime":"0","summary":"8月4日，爱德华兹生命科学盘中上涨3.1%，报88.74美元/股，成交额1.62亿美元。消息面上，近期多家华尔街投行密集上调公司评级及目标价。基本面方面，公司二季度调整后每股收益0.78美元，超出市场预期的0.74美元；营收17.41亿美元，同比增长13.7%，超出预期的17.00亿美元。此外，医疗保健设备板块整体走强，板块内直觉外科涨5.78%、史赛克涨4.06%，形成联动效应。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168381492","title":"异动解读｜爱德华兹生命科学盘中上涨6.05%，Q2业绩全面超预期且上调TAVR增长指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1168381492","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168381492?lang=zh_cn&edition=full","pubTime":"2026-07-24 21:32","pubTimestamp":1784899975,"startTime":"0","endTime":"0","summary":"7月24日，爱德华兹生命科学盘中上涨6.05%，报88.615美元/股。消息面上，公司发布第二季度财报，调整后每股收益0.78美元，超出市场预期的0.74美元，同比增长16.4%；营收17.41亿美元，高于预期的17.00亿美元，同比增长13.7%。核心产品TAVR本季度销售额达12.6亿美元，同比增长11.3%，超出市场预期。公司同时将全年TAVR销售增长预期下限从7%上调至8%。此外，Leerink Partners将公司评级从\"与大盘持平\"上调至\"跑赢大盘\"，目标价从87美元提高至101美元，进一步提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171822599","title":"Leerink Partners上调爱德华兹评级至跑赢大盘，目标价从87美元升至101美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171822599","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171822599?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:30","pubTimestamp":1784889022,"startTime":"0","endTime":"0","summary":"华尔街投行Leerink Partners调整了对爱德华兹生命科学的评级，将该公司股票从“与大盘持平”上调至“跑赢大盘”。与此同时，分析师还将目标股价从原先的87美元提高至101美元。这一动作反映出机构对爱德华兹未来前景的乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BMED","IE00BN0W2V16.EUR","BK4585","SG9999013999.USD","LU0345774631.USD","BK4588","LU0345774391.USD","IE00BFXG0V08.USD","BK4504","LU0823416689.USD","IHI","EW","BK4082","SGXZ57979304.SGD","IE00BN0W2W23.USD","IE00BYQQ9H92.USD","SG9999001176.USD","SG9999001176.SGD","BK4567","LU0289739699.SGD","IE00BN0W2T93.GBP","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150697291","title":"异动解读｜爱德华兹生命科学夜盘上涨5.57%，Q2业绩全面超预期且上调TAVR增长指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1150697291","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150697291?lang=zh_cn&edition=full","pubTime":"2026-07-24 15:26","pubTimestamp":1784877992,"startTime":"0","endTime":"0","summary":"7月24日，爱德华兹生命科学夜盘上涨5.57%，报88.49美元/股。消息面上，公司发布第二季度财报，业绩全面超出市场预期。核心产品TAVR本季度销售额达12.6亿美元，同比增长11.3%，超出市场预期的12.3亿美元。公司同时将全年TAVR销售增长预期下限从7%上调至8%，并维持全年调整后每股收益2.95至3.05美元的指引。爱德华兹生命科学在结构性心脏病及重症监护领域处于全球领先地位，专注于人工心脏瓣膜等创新疗法的研发与商业化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157520890","title":"异动解读 | 爱德华兹生命科学夜盘大涨5.76%，Q2业绩超预期且TAVR需求强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1157520890","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157520890?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:30","pubTimestamp":1784874644,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学（EW）在夜盘交易中股价大涨5.76%，引发市场关注。消息面上，公司公布了超出预期的第二季度业绩。得益于用于复杂心脏手术的人工心脏瓣膜需求强劲，其季度利润和营收均高于分析师预期。具体来看，核心产品经导管主动脉瓣置换装置（TAVR）本季度销售额同比增长11.3%，达到12.6亿美元，远超市场预期的12.3亿美元。此外，公司还将2026年TAVR设备销售额增长预期的下限从7%上调至8%，并维持了年度调整后利润预期。强劲的业绩和乐观的指引共同推动了股价在夜盘时段走高。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144791790","title":"财报前瞻｜爱德华兹本季度营收预计增14.19%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1144791790","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144791790?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:47","pubTimestamp":1784162840,"startTime":"0","endTime":"0","summary":"爱德华兹将于2026年07月23日（盘后）发布新一季度财报，市场聚焦经导管瓣膜需求与政策催化下的量价变化及利润韧性。市场一致预期本季度爱德华兹营收为17.00亿美元，同比增长14.19%；EBIT为4.79亿美元，同比增长17.60%；调整后每股收益为0.74美元，同比增长18.99%。上季度公司营收16.49亿美元，同比增长16.70%；毛利率78.01%；归属于母公司股东的净利润3.81亿美元；净利率23.09%；调整后每股收益0.78美元，同比增长21.88%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜爱德华兹本季度营收预计增14.19%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118580893","title":"异动解读｜爱德华兹盘中下跌3.21%，报87.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118580893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118580893?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:49","pubTimestamp":1784123395,"startTime":"0","endTime":"0","summary":"7月15日，爱德华兹盘中下跌3.21%，报87.25美元/股，成交额3816.34万美元。爱德华兹所在的医疗保健设备行业中，个股表现分化，其中直觉外科公司跌0.03%，雅培跌0.56%，美敦力涨0.39%，史赛克涨0.01%，波士顿科学跌0.84%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125263351","title":"异动解读｜爱德华兹盘中下跌3.28%，报89.915美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1125263351","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125263351?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:11","pubTimestamp":1784038296,"startTime":"0","endTime":"0","summary":"7月14日，爱德华兹盘中下跌3.28%，报89.915美元/股，成交额8200.87万美元。爱德华兹所在的医疗保健设备行业中，个股普遍承压，其中直觉外科公司跌3.96%，史赛克跌5.67%，雅培跌2.5%，波士顿科学跌3.67%，美敦力跌3.73%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edwards.com","stockEarnings":[{"period":"1week","weight":0.0494},{"period":"1month","weight":0.2408},{"period":"3month","weight":0.155},{"period":"6month","weight":0.3001},{"period":"1year","weight":0.2363},{"period":"ytd","weight":0.2411}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"爱德华兹生命科学公司于1999年9月10日在特拉华州注册成立。公司在结构性心脏病以及重症监护和外科监护方面处于全球领先地位。在帮助患者的热情驱使下，公司与世界领先的临床医生和研究人员合作，投资研发，以改变对结构性心脏病患者的护理，或在手术或重症监护期间需要血流动力学监测的患者的护理。","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.018112},{"month":2,"riseRate":0.576923,"avgChangeRate":0.014785},{"month":3,"riseRate":0.72,"avgChangeRate":0.019095},{"month":4,"riseRate":0.653846,"avgChangeRate":0.033225},{"month":5,"riseRate":0.740741,"avgChangeRate":0.032795},{"month":6,"riseRate":0.666667,"avgChangeRate":0.035042},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002065},{"month":8,"riseRate":0.666667,"avgChangeRate":0.019334},{"month":9,"riseRate":0.37037,"avgChangeRate":-0.01035},{"month":10,"riseRate":0.518519,"avgChangeRate":-0.024858},{"month":11,"riseRate":0.703704,"avgChangeRate":0.037497},{"month":12,"riseRate":0.615385,"avgChangeRate":0.042291}],"exchange":"NYSE","name":"爱德华兹","nameEN":"Edwards Lifesciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"爱德华兹,EW,爱德华兹股票,爱德华兹股票老虎,爱德华兹股票老虎国际,爱德华兹行情,爱德华兹股票行情,爱德华兹股价,爱德华兹股市,爱德华兹股票价格,爱德华兹股票交易,爱德华兹股票购买,爱德华兹股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}